CASIF — CASI Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.06m
- $38.79m
- $20.71m
Casi Pharmaceuticals Inc Expected To Post A Loss Of 5 Cents A Share: Earnings Preview
Brief: Casi Pharmaceuticals Partner, Bioinvent, To Present Further Positive Clinical Data On BI-1206 At Ash 2021
Brief: CASI Pharmaceuticals Inc Says May Sell From Time To Time Shares Common Stock With Aggregate Sales Price Of Up To $20 Million
Brief: CASI Pharmaceuticals Says Partner Juventas Completed Series C Financing Of $63 Mln
Brief: Casi Pharmaceuticals Announces Second Quarter 2021 Financial Results
Casi Pharmaceuticals Inc Expected To Post A Loss Of 7 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Expected To Post A Loss Of 7 Cents A Share: Earnings Preview
Brief: CASI Pharma Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Brief: CASI Pharmaceuticals Announces Q1 Revenue Of $5.7 Mln
Casi Pharmaceuticals Inc Expected To Post A Loss Of 6 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Expected To Post A Loss Of 6 Cents A Share: Earnings Preview
U.S. STOCKS ON THE MOVE-Applied Materials, Diamondback Energy, GameStop, NextDecade, Cinedigm
U.S. STOCKS ON THE MOVE-Applied Materials, GameStop, ViacomCBS, Cinedigm, Diamondback Energy
CASI Pharmaceuticals: Falls on discounted stock deal
Brief: Casi Pharmaceuticals Announces Pricing Of $32.5 Mln Public Offering Of Common Stock
Brief: CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Brief: Cleave Therapeutics Licenses First-In-Class Vcp/P97 Inhibitor Cb-5339 To Casi Pharmaceuticals For Greater China Region
Brief: Casi Pharmaceuticals Sees FY Revenue Up More Than 50%